238P BOLERO-5: A phase II study of everolimus and exemestane combination in Chinese post-menopausal women with ER+/HER2- advanced breast cancer

The results of the global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE, an mTOR inhibitor) and exemestane (EXE) in the treatment of ER+, HER2-, locally advanced, recurrent, or metastatic breast cancer (ABC). BOLERO-5 investigated this combination in Chinese post-menopausal women with ER+, HER2- ABC, refractory to letrozole or anastrozole (NCT03312738).